Schmid P, et al. - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer. ESMO Congress 2019, abstract LBA8_PR.
Behandelopties voor NET’s: een systematische review en netwerkmeta-analyse
apr 2019 | Maag-darm-leveroncologie, Overig